A New Class of Cancer Therapeutics Targeting the Inner Mitochondrial Membrane
Cancer is deeply intertwined with aging biology. As cells age, declines in mitochondrial membrane potential (MMP, ΔΨm) reshape energy production, stress resistance, and apoptotic control—changes that are similarly exploited in malignant transformation. This shared mitochondrial vulnerability has enabled an entirely new therapeutic approach to cancer therapeutics.
Perseus SENOLYTIX develops MitoXcel™ oncopeptides, a class of sequence‑engineered peptides designed to selectively target cancer cells through mitochondrial‑mediated mechanisms that differ fundamentally from receptor‑based oncology drugs.
A Platform Rooted in Aging Biology and Mitochondrial Function
Across all tissues, senescent and aging cells exhibit lower and declining ΔΨm relative to healthy, non‑senescent cells. MitoXcel™ geropeptides—developed by our affiliated longevity programs—leverage this universal energetic signature to produce two robust effects in naturally aged mice:
- Immediate restoration of mitochondrial efficiency in aging cells.
- Progressive, system‑wide elimination of senescent cells with no observed adverse effects.
These effects derive from a novel mechanism of action: recognition of ΔΨm as a biophysical, aging‑specific target rather than a receptor or enzyme.
Cancer biology reveals a parallel insight:
Many cancer cells also exhibit distinct ΔΨm characteristics compared with normal cells, positioning mitochondrial membrane potential as a therapeutically exploitable discriminator in oncology.
This observation led directly to the creation of MitoXcel™ oncopeptides through direct in vitro screening against a panel of human cancer cell lines.
Preclinical Evidence: Potent Activity Across Blood and Solid Tumors
Hematologic Cancers
In vitro, PTC‑2110 demonstrates strong activity across multiple human leukemia and lymphoma cell lines, including:
- Ph+ B‑ALL
- Ph‑like B‑ALL
- T‑ALL
- AML
In Vivo Efficacy in Aggressive B‑ALL
In a disseminated TOM‑1 (ABL1 WT, JAK2 V617F) B‑ALL model:
- PTC‑2110 significantly improved overall survival versus saline (log‑rank p = 0.0034).
- Tumor burden in lung and spleen was almost completely controlled by PTC‑2110 monotherapy or PTC‑2110 + venetoclax.
- Efficacy was equivalent to ponatinib, despite ponatinib-treated mice receiving nearly 5× greater total drug exposure and despite no ABL1‑directed activity being present in PTC‑2110.
These data highlight a mechanism that is independent of kinase pathway targeting, consistent with a ΔΨm‑selective mode of action.
Solid Tumors
Screening across a broad panel of human solid tumor cell lines identified PTC‑2128 as active against multiple cancer types, with the strongest effects observed in:
- Melanoma (4/4 cell lines)
- Breast cancer (1/2 cell lines)
This supports ΔΨm‑based targeting as a cross‑tumor therapeutic principle, not limited to hematologic malignancies.
Safety Profile and Therapeutic Potential
Across long‑term preclinical dosing studies exceeding 20 weeks, both MitoXcel™ geropeptides and MitoXcel™ oncopeptides have shown:
- No evidence of toxicity
- Stable tolerability at escalating doses
- Mechanistic specificity driven by mitochondrial bioenergetics, not receptor engagement
This safety and selectivity profile supports the potential for a fundamentally new class of cancer therapeutics—one that targets malignant cells through mitochondrial function rather than pathway inhibition.
Our Origin and Family of Companies
Founded in 2017 in Houston, Texas, SENOTHERAPEUTIX, Inc. began with a mission to develop true gerotherapeutics capable of improving healthspan and extending lifespan. The Company’s groundbreaking discoveries in geroscience and longevity biotechnology led to the creation of three wholly owned subsidiaries—each applying our core technologies to a different domain of human health.
In 2025, SENOTHERAPEUTIX, Inc. registered the Texas d/b/a GEROTHERAPEUTIX, Inc., and today its innovation pipeline is advanced through:
- Eos SENOLYTIX – Developing novel MitoXcel™ geropeptide therapeutics aimed at improving healthspan and extending lifespan.
- Perseus SENOLYTIX – An oncology company creating first‑in‑class MitoXcel™ “oncopeptides,” leveraging the same mitochondrial target to pursue safer, more selective cancer treatments.
- Phoenix SENOLYTIX – Developing next‑generation, controllable gene therapies using our proprietary ApoptiCIDe™ purposeful cell elimination technology to improve healthspan and increase lifespan.
GEROTHERAPEUTIX is executing on its bold vision to develop the iconic longevity medicine company of our time. Visit each affiliate company—and the MitoXcel™ Technology site—to learn more about the breakthrough science driving this new era of longevity medicine.
